Use of hnRNPL in preparation of glioma diagnosis, treatment and prognosis evaluation products

By detecting hnRNPL expression levels and using inhibitors targeting hnRNPL to prevent exon skipping of SH3BGRL, the unclear molecular mechanism by which hnRNPL regulates downstream target genes in gliomas has been resolved, enabling precision diagnosis and treatment of gliomas and providing new molecular targets and treatment options.

CN122104920APending Publication Date: 2026-05-29TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202610560202.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-27
Publication Date
2026-05-29

Smart Images

  • Figure CN122104920A_ABST
    Figure CN122104920A_ABST
Patent Text Reader

Abstract

The application discloses application of hnRNPL in preparation of glioma diagnosis, treatment and prognosis evaluation products, and belongs to the technical field of biological medicine. Through bioinformatics and clinical sample verification, it is confirmed that hnRNPL is significantly highly expressed in glioma tissues, and the expression level thereof is negatively correlated with the total survival period of patients, and hnRNPL has the function of promoting the occurrence and development of glioma. Mechanism research shows that hnRNPL can be used as a key alternative splicing factor, which promotes the skipping of the second exon of SH3BGRL by combining with the CA-rich sequence on the SH3BGRL pre-mRNA, thereby generating functional SH3BGRL protein, and driving the proliferation, migration and invasion of glioma cells. Based on this, hnRNPL can be used as a molecular marker for the diagnosis and prognosis evaluation of glioma, and an inhibitor targeting hnRNPL can effectively inhibit the malignant progression of glioma.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat

    US20090221673A1

  • Application of lncRNA LINREP in diagnosis, prognosis and treatment of glioma

    CN115807082A

  • Genetic, developmental and micro-environmental programs in IDH-mutant gliomas, compositions of matter and methods of use thereof

    US20230000912A1